Leung Group- Cancer Vaccines
The Leung Lab is interested in advancing the field of cancer immunotherapy by developing next-generation cancer vaccines capable of inducing robust and durable cytotoxic T-cell responses. While immune checkpoint inhibitors have revolutionized cancer treatment, their clinical benefits are limited to a subset of patients, often those with pre-existing anti-tumour T-cell activity. By contrast, cancer vaccines offer a proactive approach to stimulate the immune system and generate targeted anti-tumour responses, but their broad clinical application has been hindered by significant challenges and unanswered questions.
Our research aims to overcome these hurdles by designing and optimizing novel cancer vaccines, assessing their safety, efficacy, and mechanisms of action in preclinical models. In parallel, we investigate how components of the tumour microenvironment and combination therapies influence therapeutic responses and resistance. Gaining deeper insights into these mechanisms will support the development of more effective strategies to combat cancer and improve patient outcomes.
Our team
-
Carol Leung
Junior Group Leader
-
Orthi Onupom
Research Assistant
-
Michael Bryan
DPhil Student
-
Valerie Leung
MSc student
